Skip to content

Ligand Pharmaceuticals

US · LGND #1920 by market cap Listed 1970
286.85 -0.09 -0.03%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $345
    Market Newswire · 2026/8/7
  • Rating change
    A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $345 to $358
    Market Newswire · 2026/10/30
  • Rating change
    RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $345
    Market Newswire · 2026/8/10
  • Rating change
    BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $388
    Market Newswire · 2026/7/22
  • Rating change
    A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $388 to $397
    Market Newswire · 2026/9/23
  • Rating change
    BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $406
    Market Newswire · 2026/10/19
  • H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $358
    Market Newswire · 2026/11/12
  • Rating change
    Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $397
    Market Newswire · 2026/9/24
  • Rating change
    A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $326 to $370
    Market Newswire · 2026/8/8
  • Rating change
    Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $326
    Market Newswire · 2026/8/3
  • Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $350
    Market Newswire · 2026/11/11
  • RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $357
    Market Newswire · 2026/11/2
  • Rating change
    Barclays Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $345
    Market Newswire · 2026/9/25
  • A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $345 to $406
    Market Newswire · 2026/10/31
  • Rating change
    Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $387
    Market Newswire · 2026/7/22
  • Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $402
    Market Newswire · 2026/11/5
  • Rating change
    Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
    Market Newswire · 2026/9/24
  • Rating change
    H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $358
    Market Newswire · 2026/8/7
  • Rating change
    Stifel Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $332
    Market Newswire · 2026/8/14
  • Rating change
    Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $390
    Market Newswire · 2026/8/12
  • GUIDANCE: (LGND) Ligand Pharmaceuticals Expects 2026 Revenue Range $270M - $310M, Vs. FactSet Est of $289.5M
    MT Newswires · 2026/10/29
  • Rating change
    Benchmark Co. Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $335
    Market Newswire · 2026/7/16
  • Rating change
    H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $358
    Market Newswire · 2026/9/24
  • Rating change
    RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $340
    Market Newswire · 2026/7/15
  • Rating change
    BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $388
    Market Newswire · 2026/7/9

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Ligand Pharmaceuticals discussion 0 comments

Add a comment